CONDENSED NOTES TO
CONSOLIDATED
FINANCIAL STATEMENTS
(UNAUDITED)
1.
Description of Business
ParkerVision
(“w
e”
or
the “Company”) is
in the business of innovating fundamental wireless technologies. We design, develop and market our proprietary radio frequency (“RF”) technologies and products for use in semiconductor circuits for wireless communication products.
In addition, we offer engineering consulting and design services, for a negotiated fee, to assist customers in developing prototypes and/or products incorporating wireless technologies
.
We believe
certain patents protecting
our proprietary technologies have been broadly infringed by others and therefore our business plan
include
s
enforcement of our intellectual property rights through patent infringement litigation and licensing efforts.
2. Liquidity and Going Concern
Our
consolidated
financial statements were prepared assuming we would continue as a going concern, which contemplates that we will continue in operation for the foreseeable future and will be able to realize assets and settle liabilities and commitments in the normal course of business. These
consolidated f
inancial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.
In
January and July 2016
, we sold unregistered common stock in
two
private placement transaction
s
for
net proceeds of
approximately
$
3.8
million (see Note 10). In addition, in
2016
, we received an aggregate of
$13
million in funding from a litigation funding party,
Brickell Key Investments (“BKI”). Of the funding received,
$2
million was for general working capital purposes and the remaining
$11
million
wa
s restricted for payment of legal fees and expenses in connection with our proceedings at the International Trade Commission (“ITC”) and related
international
patent actions (see Note 8).
Our fee arrangements with regard to the ITC and related proceedings provide for fee caps such that our legal fees and expenses to prosecute these actions are not expected to exceed the restricted funds received.
We received approximately
$3.3
million in
net
proceeds from a patent license and settlement agreement in August 2016
. T
hese proceeds were used to repay a portion of the BKI funding.
At
September
30
, 2016, we had cash, cash equivalents, and available-for-sale securities of approximately
$
1.1
million and restricted cash and cash equivalents of approximately $
2.7
million. We used approximately
$
11.8
million of cash for operations
during the
nine
months ended
September
30
, 2016, of which approximately
$
8.
3
million was funded from restricted cash and cash equivalents
for our ITC and related proceedings
. Our unrestricted capital resources at
September
30
, 2016
will
not be
sufficient to support our
working capital
requirements for
the next twelve months
. This raises substantial doubt about our ability to continue as a going concern.
Our ability to meet our operating costs for 2016
and beyond
is dependent upon our ability to (i) successfully negotiate licensing agreements and/or settlements
relating to
the use of our technologies by others and/or (ii) our ability to develop, market and sell existing and new products.
Funds received from
future patent license and litigation settlement agreements will first be designated for repayment of our secured contingent payment obligation
.
Thereafter, any remaining revenues from patent-related activities will be subject to prorated contingent payments to third-parties, including legal counsel.
We expect that revenue generated from patent enforcement actions, technology licenses and/or the sale of products in 2016
will
not be sufficient to cover our operating expenses and our secured contingent repayment obligations.
We expect to continue to invest in patent prosecution and enforcement, product development, and sales, marketing, and customer support for our technologies and products. The long-term continuation of our business plan is dependent upon the generation of sufficient revenues from our technologies and/or products to offset expenses and contingent payment obligations. In the event that we do not generate sufficient revenues, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs. Failure to generate sufficient revenues, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.
3. Basis of Presentation
The accompanying unaudited
consolidated
financial statements for the period ended
September
30
, 2016
were prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Operating results for the three
and
nine
months ended
September
30
, 2016
are not necessarily indicative of the results that may be expected for the year ending December 31, 201
6
or future years.
Certain reclassifications have been made to prior period
amounts to conform to the current period presentation.
All prior period references in these
unaudited
consolidated
financial statements to number of shares, price per share and weighted average shares of common stock have been adjusted on a retroactive basis to reflect the one-for-ten reverse stock split that went into effect on March 30, 2016.
All normal and recurring adjustments which, in the opinion of management, are necessary for a fair
statement
of the financial condition and results of
operations have been included.
The year-end
consolidated
balance sheet data was derived from audited financial statements
for the year ended December 31, 201
5
, but does not include all disclosures required by accounting principles generally accepted in the United States of America.
These interim
consolidated
financial statements should be read in conjunction with our latest Annual Report on Form 10-K for the year ended December 31, 201
5
.
The consolidated financial statements include the accounts of ParkerVision, Inc. and its wholly-owned
German
subsidiary, ParkerVision GmbH (collectively, “ParkerVision”) after elimination of all intercompany transactions and accounts.
4. Accounting Policies
There have been no changes in accounting policies from those stated in our Annual Report on Form 10-K for
the year ended December 31, 2015,
except as follows:
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents represent cash on hand and money market investments that are restricted for specific use in payment of legal fees and expenses related to certain of our patent infringement actions. The restricted money market investments have
weighted average
maturities of three months or less when purchased and are recorded at fair value. We have determined that the fair value of our restricted money market investments fall within Level 1 in the fair value hierarchy (see Note 11).
Secured Contingent Payment Obligation
We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 11). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest,
are
included in the accompanying consolidated statements of comprehensive loss under the heading “
Change in fair value of contingent payment obligation
”.
Revenue Recognition
We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes, sales of integrated circuit products, and engineering services. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when there is persuasive evidence of an arrangement, the amounts are fixed and determinable and the collectability is reasonably assured.
Revenue from the sale of products is recognized at the time of shipment to the customer or when the other criteria for revenue recognition are met, if later. Revenue from providing services is recognized when earned. Unearned revenue consists of product inventory held by a distributor and retainer payments received on services contracts.
The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded
as
revenue in our consolidated statement of
comprehensive loss
when earned. We recognize revenues upon execution of a patent license and settlement agreement by both parties provided that the amounts are fixed and determinable, there are no significant undelivered obligations and collectability is reasonably assured. We do not recognize any revenue prior to the execution of an agreement as there is no reliable basis on which we can estimate the amounts related to the elements of the arrangement, or assess collectability. In addition, we do not recognize as revenue any consideration in the agreement that is contingent upon the occurrence of future events until such time that those future events occur.
Accounting for Share-Based Compensation
In April 2016, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-09,
“Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09
simplifies several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. We have elected to account for forfeitures of share-based equity awards as they occur. The adoption of ASU 2016-09 had no impact on our consolidated financial statements except for the reclassification of the value of shares withheld for payment of taxes in our accompanying consolidated statements of cash flows.
Recent Accounting Pronouncements
In
August
2016, we early adopted FASB ASU 2016-15
“
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.
”
This update provides guidance on the presentation and classification of certain items on the statement of cash flows
. The adoption of ASU 2016-15 had no effect on our current or prior period consolidated financial statements.
In April 2016, we early adopted, on a retrospective basis, FASB ASU 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes (Topic 740)”, issued in November 2015. ASU 2015-17 simplifies the presentation of deferred income taxes by requiring that all deferred tax liabilities and assets be classified as noncurrent in the consolidated balance sheet. Given the existence of a full valuation allowance for all periods presented, the adoption of ASU 2015-17 had no effect on our current or prior period consolidated financial statements.
In April 2016, we early adopted FASB ASU 2015-11, “Simplifying the Measurement of Inventory (Topic 330)” issued in July 2015. ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out method by prescribing inventory be valued at the lower of cost and net realizable value. The adoption of ASU 2015-11 had no impact on our consolidated financial
statements
.
In February 2016, the FASB issued ASU 2016-02 “Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018. Early adoption is permitted. We are currently assessing the impact of this update on our consolidated financial statements.
In August 2014, the FASB issued ASU 2014-15
“Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,”
to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for interim and annual periods beginning after December 15, 2016. Early adoption is permitted. W
e
are
currently formalizing processes
and controls to assess risk, determine the level of analysis necessary and to perform our going concern assessment in accordance with ASU 2014-15.
In May 2014, the FASB issued ASU 2014-09,
“Revenue from Contracts with Customers.”
ASU 2014-09 implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. ASU 2015-14,
“Revenue from Contracts with Customers (Topic 606)”,
issued in August 2015, defers adoption of ASU 2014-09 to annual reporting periods beginning after December 15, 2017. Early adoption is not permitted. We do not expect the adoption of ASU 2014-09 to have a material effect on our consolidated financial statements.
5
.
Loss per Common Share
Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each period. Diluted loss per common share is the same as basic loss per common share as all common share equivalents are excluded from the calculation, as their effect is anti-dilutive.
O
ptions and warrants to purchase
1,025,846
and
1
,
308
,
66
9
shares
of common stock were outstanding at
September
30
, 2016 and 2015
, respectively. In addition, unvested restricted stock units (“RSUs”), representing
325,000
and
75
,
83
4
shares of common stock, were outstanding at
September
30, 2016
and 2015, respectively
. These options, warrants and RSUs were excluded from the computation of diluted loss per common share as their effect would have been anti-dilut
ive.
6
.
Inventories
Inventories consist of the following
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
December 31,
|
|
|
|
2016
|
|
2015
|
|
Work-in-process
|
|
$
|
126,725
|
|
$
|
117,045
|
|
Finished goods
|
|
|
43,325
|
|
|
43,731
|
|
Total inventories
|
|
$
|
170,050
|
|
$
|
160,776
|
|
|
|
|
|
|
|
|
7
. Intangible Assets
Intangible assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2016
|
|
|
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
Book Value
|
|
Patents and copyrights
|
|
$
|
20,422,143
|
|
$
|
13,600,907
|
|
$
|
6,821,236
|
|
Prepaid licensing fees
|
|
|
574,000
|
|
|
574,000
|
|
|
-
|
|
|
|
$
|
20,996,143
|
|
$
|
14,174,907
|
|
$
|
6,821,236
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2015
|
|
|
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
Book Value
|
|
Patents and copyrights
|
|
$
|
20,309,630
|
|
$
|
12,734,697
|
|
$
|
7,574,933
|
|
Prepaid licensing fees
|
|
|
574,000
|
|
|
574,000
|
|
|
-
|
|
|
|
$
|
20,883,630
|
|
$
|
13,308,697
|
|
$
|
7,574,933
|
|
|
|
|
|
|
|
|
|
|
|
8. Long-Term Debt
Note Payable to a Related Party
A
t
September
30
, 2016
, we had an
unsecured promissory note payable to a related party for unpaid legal fees
of
$825,000
. Interest on the note is payable monthly on the outstanding principal balance at a rate of
8%
per annum. The note matures on
December 31, 2017
and early prepayment of all or any portion of the principal balance is allowed without penalty.
As of
September
30
, 2016, the estimated fair value of our note payable is approximately
$
7
34
,000
based on a risk-adjusted discount rate
.
Failure to comply with the
payment
terms of this note constitutes an event of default which, if uncured, will result in the entire unpaid principal balance of the note and any unpaid, accrued interest to become immediately due and payable. As of
September
30
, 2016, we are in compliance with
the payment term
s of the note.
Secured Contingent Payment Obligation
On February 25, 2016, we entered into a litigation funding arrangement with BKI, a special purpose fund under the management of Juridica Asset Management Limited. Under the agreement, we received aggregate proceeds of
$11
million in exchange for BKI’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. In connection with the agreement, we issued BKI a warrant to purchase up to
250,000
shares of our common stock at an exercise price of
$3.50
per share valued at its estimated fair market value of
$
1
55,625
using a
discounted
Black-Scholes model
.
In May 2016, we received additional proceeds of
$2
million from BKI. In connection with the additional proceeds, we exchanged
the
original w
arrant for a new warrant to purchase up to
350,000
shares of our common stock at an exercise price of
$2.00
per share.
We
estimated the incremental fair value of the
new warrant
of
$179,3
05
using a
discounted Black-Scholes model
.
The aggregate fair value of the
BKI
w
arrant
is
$334,930
and is
included in shareholders’
(
deficit
) equity
in the accompanying consolidated balance sheet at
September
30, 2016.
Under the agreement
s
, $1
1
million of the
aggregate
proceeds are restricted for use in payment of our legal fees and expenses in connection with the legal proceedings filed
at the ITC
in December 2015
and legal proceedings filed in Germany in June 2016
(the “Funded Actions”). These proceeds, net of funds used to pay allowable expenses or funds paid on retainer, are recorded as restricted cash and cash equivalents on our accompanying
consolidated
balance sheet
at
September
30
, 2016
.
BKI is entitled to priority payment of
100%
of proceeds
received
from all patent-related actions until such time that BKI has been repaid in full. After repayment of the funded amount, BKI is entitled to a portion of remaining proceeds up to a specified minimum return which is determined as a percentage of the funded amount and varies based on the timing of repayment. In addition, BKI is entitled to a pro rata portion of proceeds solely from the Funded Actions to the extent
aggregate proceeds from the
Funded Action
s
exceed the specified minimum return.
We granted BKI a senior security interest in our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds directly related to Funded Actions. The security interest is enforceable by BKI in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to BKI, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without BKI’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under
the agreement. As of
September
30
, 2016, we are in compliance with our obligations under this agreement.
We have elected to measure our secured contingent payment obligatio
n at fair value
based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods
.
The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved.
As of
September
30
, 2016, the fair value of the obligation is estimated to be
$
1
2,357,697
(see Note 11).
9. Share-Based Compensation
There has been no material change in the assumptions used to compute the fair value of our equity awards, nor in the method used to account for sha
re-based compensation from those stated in our Annual Report on Form 10-K for the year ended December 31, 201
5, except for the adoption of ASU 2016-09 as discussed in Note 4
.
The following table presents share-based compensation expense included in our
consolidated
statements of
comprehensive loss
for the
three and
nine
months ended September 30, 2016 and 2015
, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
September 30,
|
|
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
Research and development expenses
|
|
$
|
328,631
|
|
$
|
82,670
|
|
$
|
379,836
|
|
$
|
204,928
|
|
Selling, general and administrative
expenses
|
|
|
1,094,312
|
|
|
113,347
|
|
|
1,107,852
|
|
|
878,349
|
|
Total share-based expense
|
|
$
|
1,422,943
|
|
$
|
196,017
|
|
$
|
1,487,688
|
|
$
|
1,083,277
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On August 15, 2016, we granted an aggregate of
200,000
restricted stock units (“RSU”) with a total grant date fair value of
$1,226,000
to our non-employee directors.
One-half
of the RSUs
vested
upon grant
and the remaining half vest on August 15, 2017. Also on August 15, 2016, we granted an aggregate of
30
0,000
RSUs with a total grant date fair value of
$1,
839
,000
to
employees, including certain of our named executive officers
.
These
RSUs
vest in
four
, equal
quarter
ly
increments beginning on September 1, 2016
.
As of
September 30, 2016
, we had
approximately
$1,860,000
in
unrecognized compensation cost related to unvested share-based compensation awards. This cost is expected to be recognized over a weighted average period of approximatel
y
one
year
.
On August 12, 2016, our shareholders approved an amendment to our 2011 Long-Term
Incentive
Equity Plan
to
increase the shares authorized for issuance under the plan from
1,200,000
to
1,950,000
shares.
As of September 30, 2016, we have an aggregate of
815,877
available for grant under approved equity plans.
10
. Stock Authorization and Issuance
On August 17, 2016, we amended our articles of incorporation to increase the number of authorized shares of common stock from
15,000,000
to
20,000,000
shares. This amendment was approved by our shareholders on August 12, 2016.
On January 25, 2016, we sold
454,546
shares of our common stock at a price of
$2.20
per share to an accredited investor in a private placement transaction generating gross proceeds of approximately
$1,000,000
. We
ha
ve
no registration obligations with respect to these shares.
On February 25, 2016, we issued a warrant to BKI for the purchase of up to 250,000 shares of our common stock in conjunction with their financing arrangement with us (see Note 8). The warrant had an exercise price of $3.50 per share, was exercisable for
five
years from the date of issuance, and had piggy-back registration rights of the underlying warrant shares. On May 27, 2016, in connection with an additional financing arrangement with BKI (see Note 8), the warrant was exchanged for a new warrant for the purchase of up to 350,000 shares of our common stock at an exercise price of $2.00 per share. The new warrant is exercisable for five years from the date of issuance and has piggy-back registration rights of the underlying warrant shares. The shares underlying the warrants were registered on a registration statement that was declared effective on August 2, 2016 (File No. 333-212670).
On March 29, 2016, we effected a
one-for-ten
reverse stock split of our common stock, and our common stock began trading on the NASDAQ capital market on a post-split basis at the open of business on March 30, 2016. As a result of the reverse stock split, every ten shares of our common stock was combined into one share of our common stock. No fractional shares of our common stock were issued in connection with the reverse stock split. Any fractional shares created as a result of the reverse stock split were rounded up to the next largest whole number. The par value and other terms of our common stock
were
not affected by the reverse stock split. However, the number of shares of common stock that we are authorized to issue was proportionately reduced from
150,000,000
shares to
15,000,000
.
On April 12, 2016,
we issued
200,000
shares of unregistered common stock to
an
outside
consultant
in exchange for a
$310,000
prepaid retainer for consulting services.
We have no registration obligation with respect to these shares.
In July 2016, we sold
1,090,909
shares of our common stock at a price of
$2.75
per share to an accredited investor in a private placement transaction generating
gross
proceeds of approximately
3,0
00,000
. We filed a registration statement on July 25, 2016 to register the resale of the common stock and the registration statement was declared effective on August 2, 2016 (File No. 333-212670).
In July 2016, we also exchanged warrants issued in 2015 to 1624 PV, LLC (“1624”) for a new warrant. We exchanged
three
common stock
purchase warrants,
each entitling 1624 to acquire up to
188,406
shares of our common stock at exercise prices of
$15
,
$25
and
$35
, respectively for a new warrant entitling 1624 to acquire up to
200,000
shares of our common stock at an exercise price of
$3.25
per share with an expiration date of
June 16, 2018
. All other terms of the warrant remained unchanged. As a result of this warrant exchange, the number of shares of our common stock subject to warrants decreased by
365,218
shares
and we recognized incremental compensation cost of approximately
$103,000
which is included in share-based compensation expense
.
We
file
d
a post-effective amendment to the previously filed S-3 registration statement (File No. 333-202802) covering the resale of the shares issuable upon exercise of the warrants. This post-effective amendment was declared effective on August 3, 2016
.
On
September 1
, 2016,
we issued
45,000
shares of unregistered common stock to
an
outside
consultant
i
n exchange for a
$120,000
prepaid retainer for
executive consulting and advisory
services.
We have no registration obligation with respect to these shares.
11
. Fa
ir Value Measurements
ASC 820, “Fair Value Measures” establishes a fair value hierarchy based on three levels of inputs:
|
|
·
|
|
Level 1: Quoted prices for identical assets or liabilities in active markets which we can access
|
|
|
·
|
|
Level 2: Observable inputs other than those described in Level 1
|
|
|
·
|
|
Level 3: Unobservable inputs
|
We determine the fair value of our available-for-sale securities and restricted cash equivalents using a market approach based on quoted prices in active markets (Level 1 inputs). We measure our secured contingent payment obligation at its estimated fair value using an income approach based on the estimated present value of projected future cash outflows (Level 3 inputs). Increases or decreases in the unobservable Level 3 inputs would result in higher or lower fair value measurement.
For the three and nine months ended September 30, 2016, we had
no
transfers of assets or
liabilities
between the levels of the hierarchy.
The following table
s
summarize the fair value of our assets and liabilities measured at fair value on a recurring basis as of
September 30
, 2016
and December 31, 2015
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements
|
|
|
|
Total Fair Value
|
|
Quoted Prices
in Active
Markets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
September 30, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
$
|
57,194
|
|
$
|
57,194
|
|
$
|
-
|
|
$
|
-
|
|
Available-for-sale securities
|
|
|
628,674
|
|
|
628,674
|
|
|
-
|
|
|
-
|
|
Restricted cash equivalents
|
|
|
2,737,321
|
|
|
2,737,321
|
|
|
-
|
|
|
-
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Secured contingent payment
obligation
|
|
|
12,357,697
|
|
|
-
|
|
|
-
|
|
|
12,357,697
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements
|
|
|
|
Total Fair Value
|
|
Quoted Prices
in Active
Markets
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
December 31, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Available-for-sale securities
|
|
$
|
1,789,947
|
|
$
|
1,789,947
|
|
$
|
-
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in the fair value of our Level 3 secured contingent payment obligation for the
nine
months ended
September 30
, 2016 were as follows
:
|
|
|
|
|
|
|
|
|
|
|
|
|
Secured
Contingent
Payment
Obligation
|
|
Balance at December 31, 2015
|
|
$
|
-
|
|
Issuance of contingent payment obligation
1
|
|
|
12,665,070
|
|
Repayment
|
|
|
(3,339,980)
|
|
Change in fair value
|
|
|
3,032,607
|
|
Balance at September 30, 2016
|
|
$
|
12,357,697
|
|
|
|
|
|
1- Recorded net of $334,930 fair value assigned to the warrants issued in connection with the transaction (see Note 8).
12
. Commitments and Contingencies
Legal Proceedings
From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) in an attempt to invalidate certain of our patent claims. These patent-related proceedings are more fully described below.
Although there is at least a reasonable possibility of an unfavorable outcome in any one or more of these matters, we believe that any such outcome is not expected to have a material im
pact on our financial position or
results of operation
s
.
ParkerVision vs. Qualcomm, Inc.
On July 20, 2011, we filed a patent infringement action in the United States District Court of the Middle District of Florida (the “Middle District of Florida”) against Qualcomm Incorporated (“Qualcomm”) seeking damages and injunctive relief for infringement of several of our patents related to radio-frequency receivers and the down-conversion of electromagnetic signals. Qualcomm filed a counterclaim against us alleging invalidity and unenforceability of each of our patents. In October 2013, a jury found that all of Qualcomm’s accused products directly and indirectly infringed all
eleven
claims of the
four
patents asserted by us and awarded us
$172.7
million in damages. The jury also found that Qualcomm did not prove its claims of invalidity for any of the eleven claims of the four patents in the case, and furthermore found that we did not prove our claims of willfulness, which would have allowed enhancement of the jury-awarded damages. On June 20, 2014, a final district court ruling was issued in which the court overturned the jury’s verdict of infringement thus nullifying the damages award. We appealed this decision to the U.S. Court of Appeals for the Federal Circuit (“CAFC”) and Qualcomm filed a counter-appeal on the issues of validity and damages. On July 31, 2015, the appellate court upheld the district court’s determination of non-infringement and overturned the district court’s decision on validity, ruling that
ten
of the eleven patent claims in the case were invalid. On October 2, 2015, the CAFC denied our petition for a rehearing with respect to infringement of the one claim that was not invalidated by the CAFC. On February 29, 2016, we filed a petition with the Supreme Court of the United States (“Supreme Court”) in this matter. On March 28, 2016, the Supreme Court denied our petition requesting a review of the appellate court’s decision. We have no further appeals available to us in this action.
ParkerVision vs. Qualcomm, HTC, and Samsung
On May 1, 2014, we filed a complaint in the Middle District of Florida against Qualcomm, Qualcomm Atheros, Inc., and HTC (HTC Corporation and HTC America, Inc) (the “Qualcomm Action”) seeking unspecified damages and injunctive relief for infringement of
seven
of our patents related to RF up-conversion, systems for control of multi-mode, multi-band communications, baseband innovations including control and system calibration, and wireless protocol conversion. On August 21, 2014, we amended our complaint adding Samsung as a defendant. We also added infringement claims of
four
additional patents to this case. On November 17, 2014, certain of the defendants filed counterclaims of non-infringement and invalidity for all patents in the case. A claim construction hearing was held on August 12, 2015 but no ruling on claim construction has been issued by the court. In January 2016, the court granted the parties’ joint motion to dismiss claims and counterclaims related to
six
patents in the case in order to narrow the scope of the litigation. In February 2016, the court granted the parties’ joint motion to stay these proceedings until resolution of the proceedings at the ITC as discussed below. In July 2016, we entered into a confidential patent license and settlement agreement with Samsung and, as a result, the court granted our motion to remove Samsung from these proceedings.
Qualcomm Inc. and Qualcomm Atheros, Inc. vs. ParkerVision
On August 27, 2015, Qualcomm, Inc. and Qualcomm Atheros, Inc. filed
an
aggregate of
ten
petitions for
Inter partes
review (“IPR”) with the PTAB seeking to invalidate certain claims related to three of the eleven patents originally asserted in our Qualcomm Action. We filed preliminary responses to these petitions in December 2015. In March 2016, the PTAB issued decisions denying institution of trial for
three
of the petitions, all of which relate to our U.S. patent 7,039,372 (“the ‘372 Patent”) and instituting trial for the remaining petitions, all of which relate to our U.S. patent 6,091,940 (the ‘940 Patent”) and U.S. patent 7,966,012 (“the ‘012 Patent”). The ‘372 Patent and the ‘940 Patent are among the patents asserted in the Qualcomm Actio
n. On May 2, 2016, we entered a motion disclaiming the challenged claims of the ‘012 Patent and, on May 5, 2016, the PTAB granted our motion and entered an adverse judgment against us with respect to those claims.
Our responses to the remaining petitions that were instituted for trial were
filed
in
May 2016 and replies from Qualcomm
were filed in September
2016.
Oral arguments with regard to the remaining claims in the ‘940 patent are scheduled for November 29, 2016.
ParkerVision v. Apple, LG, Samsung and Qualcomm
On December 15, 2015, we filed a complaint with the United States ITC against Apple, Inc., LG Electronics, Inc., LG Electronics U.S.A., Inc., and LG Electronics MobileComm U.S.A., Inc., (collectively, “LG”), Samsung and Qualcomm alleging that these companies have engaged in unfair trade practices by unlawfully importing into the U.S. and selling various products that infringe
certain
of our patents. We also requested that the ITC bar the defendants from continuing to import and sell infringing products in the U.S. In December 2015, we also filed a corresponding patent infringement complaint in the Middle District of Florida against these same defendants seeking undisclosed damages for the alleged infringement of the same patents. In January 2016, the ITC instituted an investigation based on our complaint. In February 2016, the district court proceedings were stayed pending resolution of the proceedings at the ITC. In July 2016, we entered into a confidential patent license and settlement agreement with Samsung and, as a result, Samsung has been removed from both the ITC and related district court action. The ITC hearing with regard to the remaining defendants is scheduled for March 2017.
ParkerVision v. LG
In June 2016, we filed a complaint in Munich Regional Court against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc. (“LG”) seeking damages and injunctive relief for the alleged infringement of one of our German patents. A hearing in this case was held on November 10, 2016.
On November 14, 2016, the court concluded that certain LG products using Qualcomm RF circuitry infringe our patent. Subject to successful completion of the co-pending nullity action in the German Federal Patent Court in Munich, the regional court will enjoin the sale and importation of these LG products in Germany. The nullity action is a validity only challenge and a ruling in the nullity proceeding is expected as early as the first half of 2017.
ParkerVision v. Apple
In October 2016, we filed a complaint in Munich Regional Court against Apple, Inc., Apple Distribution International, and Apple Retail Germany B.V. & Co. KG (collectively, “Apple”) seeking damages and injunctive relief for the alleged infringement of the same German patent as in the LG case. A hearing has been scheduled for May 2017.
IT
EM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
We believe that it is important to communicate our future expectations to our shareholders and to the public. This quarterly report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, in particular, statements about our future plans, objectives, and expectations contained in this Item. When used in this quarterly report and in future filings by us with the Securities and Exchange Commission (“SEC”), the words or phrases “expects”, “will likely result”, “will continue”, “is anticipated”, “estimated” or similar expressions are intended to identify “forward-looking statements.” Readers are cautioned not to place undue reliance on such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and those presently anticipated or projected, including the risks and uncertainties identified in our annual report on Form 10-K for the fis
cal year ended December 31, 2015
(the “Annual Report”) and in this Item 2 of Part I of this quarterly report. Examples of such risks and uncertainties include general economic and business conditions, competition, unexpected changes in technologies and technological advances, the timely development and commercial acceptance of new products and technologies, reliance on key business and sales relationships, reliance on our intellectual property, the outcome of our intellectual property litigation and the ability to obtain adequate financing in the future. We have no obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect anticipated events or circumstances occurring after the date of such statements.
Corporate Website
We webcast our earnings calls and certain events we participate in or host with members of the investment community in the investor relations section of our website. Additionally, we announce investor information, including news and commentary about our business, financial performance and related matters, SEC filings, notices of investor events, and our press and earnings releases, in the investor relations section of our website (
http://ir.parkervision.com
). Investors and others can receive notifications of new information posted in the investor relations section in real time by signing up for email alerts and/or RSS feeds. Further corporate governance information, including our governance guidelines, board committee charters, and code of conduct, is also available in the investor relations section of our website under the heading “Corporate Governance.” The content of our website is not incorporated by reference into this quarterly report or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.
Overview
We are in the business of innovating fundamental wireless technologies. We design, develop and market our proprietary radio frequency (“RF”) technologies and products for use in semiconductor circuits for wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore our business plan includes enforcement of our intellectual property rights through patent infringement litigation and licensing efforts.
We have a three-part growth strategy that includes
product and component sales and design services,
intellectual property licensing and/or product ventures,
and
intellectual property enforcement. We have made significant investments in developing and protecting our technologies and products, the returns on which are dependent upon the generation of future revenues from
product sales and/or
licensing for realization.
Recent Events
German Patent Infringement Case Against LG
On November 14, 2016, following a November 10, 2016 hearing, the Munich regional district court confirmed its September
preliminary opinion concluding that certain LG products using Qualcomm RF circuits infringe a ParkerVision wireless transmitter patent. Subject to successful completion of the co-pending nullity action in the German Federal Patent Court in Munich, the regional court will enjoin the sale and importation of LG products in Germany. The nullity action before the German Federal Patent Court is a validity only challenge. A ruling in the nullity proceeding is expected as early as the first half of 2017.
Patent License and Settlement Agreement with Samsung
On July 15, 2016, we entered into a patent license and settlement agreement with Samsung Electronics Co., Ltd. and its affiliates (“Samsung”). Under the terms of the agreement, we granted Samsung a perpetual, worldwide license to our current patent portfolio, subject to certain exclusions. We also agreed to terminate Samsung from the U.S. International Trade Commission (“ITC”) investigation and to dismiss our claims against Samsung in two district court cases. Refer to “Legal Proceedings” in Note
12
to the
condensed consolidated
financial statements included in
this quarterly report
for a further discussion of these cases.
We recognized revenue from Samsung during the three months ended September 30, 2016 in connection with this agreement
.
Additional amounts may be received in the future related to this agreement that are not recognized in our consolidated financial statements for the three and nine months ended September 30, 2016
.
Liquidity and Capital Resources
At
September
30, 2016, our capital resources consisted of approximately
$1.1 m
illion in cash, cash equivalents and available-for-sale securities and approximately
$2.7
million in restricted cash and cash equivalents. The restricted cash and cash equivalents represents the unused portion of the re
stricted funds received from BKI
.
We used cash for operations of approximately
$2.9 million and $11.8 million for the three and nine months ended September 30, 2016, respectively, of which $2.4 million and $8.3 million, respectively, was
funded from restricted cash and cash equivalents. Our arrangements with
our attorneys for
the ITC and related proceedings provide for fee caps such that our
legal fees and expenses are not expected to
exceed the restricted funds received.
However, o
ur unrestricted capital resources at
September 30
, 2016
, are not
sufficient to support our
working capital
requirements for
the next twelve months
which raises substantial doubt about our ability to continue as a going concern.
Our repayment obligation to BKI is recorded as a long-term liability in our accompanying
consolidated
balance sheets and is measured at its estimated fair value at the end of each reporting period.
We repaid $3.3 million of this obligation during the three months ended September 30, 2016.
As of
September
30, 2016, the fair value of the
remaining
obligation is estimated to b
e $12,3
57,697
. In addition, we have an unsecured promissory note for $825,000 t
o a related party that matures on
December
31,
2017.
Our ability to meet our operating costs for 2016 is dependent upon our ability to (i) successfully negotiate licensing agreements and/or settlements for the use of our technologies by others and/or (ii) our ability to develop, market and sell existing and new products.
Funds received from future patent license and litigation settlement agreements will first be designated for repayment of our secured contingent payment obligation.
Thereafter, any remaining revenues from patent-related activities will be subject to prorated contingent payments to third-parties, including legal counsel.
In general, we
expect that revenue generated from patent enforcement actions, technology licenses and/or the sale of products
and the sale of services
in 2016
will
not be sufficient to cover our operating expenses and our secured contingent repayment obligations.
We expect to continue to invest in patent prosecution and enforcement, product development, and sales, marketing, and customer support for our technologies and products. The long-term continuation of our business plan is dependent upon the generation of sufficient revenues from our technologies and/or products to offset expenses and contingent payment obligations. In the event that we do not generate sufficient revenues, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs. Failure to generate sufficient revenues, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.
Results of Operations for Each of the Three and
Nine
Months Ended
September
30, 2016 and 2015
We use both generally accepted accounting principles (“GAAP”) and non-GAAP financial measures for assessing our consolidated results of operations. The non-GAAP measures we use include Adjusted Net Loss and Adjusted Net Loss per Share. These non-GAAP measures exclude the effect on net loss and net loss per share of (i) changes in fair value of our secured contingent payment obligation and (ii) share-based compensation expense. Share-based compensation is a non-cash expense item that is subject to significant fluctuation in value based on the volatility of the market price of our common stock, and the expense recognized on a GAAP basis is not necessarily indicative of the compensation realized by our executives, employees and non-employee directors. The change in fair value of our secured contingent payment obligation is subject to significant estimates and assumptions regarding future events and, similar to interest on long-term debt obligations, is a reflection of our cost of financing rather than our operating activities. Accordingly, we consider these non-GAAP measures to provide relevant supplemental information to assist investors in better understanding our operating results. These non-GAAP measures should not be considered a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.
Refer to “Reconciliation of Non-GAAP Financial Measures” in this section for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures for the three and nine months ended September 30, 2016.
Revenue and Gross Margin
Our revenue increased approximately $3,995,000 during the three month period ended September 30, 2016 when compared to the same period in 2015. For the nine month period ended September 30, 2016, our revenue increased approximately $4,059,000 when compared to the same period in 2015.
Our gross margin increased approximately $3,699,000 during the three month period ended September 30, 2016 when compared to the same period in 2015. For the nine month period ended September 30, 2016, our gross margin increased approximately $3,722,000 when compared to the same period in 2015. Cost of sales for the three and nine months ended September 30, 2016 consisted primarily of patent amortization expense.
The increase in revenue and margin for both the three and nine month periods is the result of licensing and settlement revenue and related cost recognized in the third quarter of 2016.
For the three and nine months ended September 30, 2015, our revenue consisted primarily of product and service revenue. Our cost of sales for product and services
include
d
the
cost of materials
,
labor and overhead incurred under
our
engineering
services
contracts.
Research and Development Expenses
Research and development expenses consist primarily of engineering and related management and support personnel costs; fees for outside engineering design services which we use from time to time to supplement our internal resources; depreciation expense related to our assets used in product development; prototype production and materials costs, which represent the fabrication and packaging costs for prototype integrated circuits, as well as the cost of supporting components for prototype board development; software licensing and support costs, which represent the annual licensing and support maintenance for engineering design and other software tools; and rent and other overhead costs for our engineering design facility. Personnel costs include share-based compensation amounts which have been determined based on the grant date fair value of equity-based awards to our employees and then recorded to expense over the vesting period of the award.
Our research and development expenses
in
creased approximately $
261,000
, or
32
%, during the three months ended
September
30, 2016 when compared to the sa
me period in 2015. This is primarily the result of an increase in share-based compensation as a result of new awards granted to engineering executives and employees in August 2016.
Our research and development expenses decreased approximately $
1,190,000
, or
32
%, during the
nine
months ended
September
30, 2016 when compared to the same period in 2015.
This decrease is
primarily due to a reduction in personnel and related expenses
following
a June 2015 workforce reduction.
Selling, General, and Administrative Expenses
Selling, general and administrative expenses consist primarily of executive, director, sales and marketing, and finance and administrative personnel costs, including share-based compensation,
and costs incurred for insurance, shareholder relations and outside legal and professional services, including litigation expenses.
Our selling, general and administrative expenses increased approximately $
1,248,000
or
54
%,
during the three months ended
September
30, 2016 when compared to the same period in 2015.
This is the result of an increase in litigation fees and expenses of approximately $565,000 and an increase in share based compensation expense of approximately $981,000, partially offset by a $279,000 decrease in amortization expense
.
Our selling, general and administrative expenses increased approximately $
3,274,000
or
33
%,
during the
nine
months ended
September
30, 2016 when compared to the same period in 2015. This is the result of an increase in litigation fees
and expenses
of approximately $
3,925,000 and an increase in
share-based compensation expense of approximately $
230,000, partially offset by a
decrease in personnel and related expenses of approximately $
519,000 and a decrease in amortization expense of approximately $270,000
.
The increase in litigation related fees and expenses for three and
nine
months ended
September
30, 2016 is
the result of increased patent-
related legal activities to support our ITC case and our German litigation
(see Note 12 to our condensed consolidated financial statements included in this quarterly report)
. These increased costs are
primarily
funded from our restricted cash and cash equivalents.
The increase in share-based compensation expense for the three and nine months ended September 30, 2016 is the result of equity awards granted to directors and executives in August 2016, partially offset by
a decrease in expense attribution related to executive long-term equity incentive awards from prior years that became fully vested in mid-2015. The decrease in personnel and related expenses is primarily the result of our June 2015 reduction in workforce.
The decrease in amortization expense for the three and nine month periods is due to the inclusion of patent amortization expense for the three months ended September 30, 2016 in cost of sales.
Change in Fair Value of Contingent Payment Obligation
We have elected to measure our secured contingent payment obligation at fair value which is based on significant unobservable inputs. We estimated the fair value of our secured contingent payment obligation using an income approach based on the estimated present value of projected future cash outflows using a risk-adjusted discount rate. Increases or decreases in the significant unobservable inputs could result in significant increases or decreases in fair value.
For the three and nine months ended September 30, 2016, the fair value of our secured contingent payment obligation increased by approximately $726,000 and $3,033,000, respectively. This increase is a result of changes in the estimated timing and amount of projected future cash outflows resulting from the funded actions.
Adjusted Net Loss and Adjusted Net Loss Per Share
Adjusted net loss decreased by approximately $2.8 million, or 94%, during the three months ended September 30, 2016 when compared to the same period in 2015. The decrease in adjusted net loss is a result of t
he increase in revenue,
somewhat offset by increases in litigation fees and expenses related primarily to our ITC action. On a per share basis, our adjusted net loss per common share decreased by $0.29 per share, or 97%. This decrease is a result of the decrease in our adjusted net loss and a 30% increase in our weighted average common shares outstanding.
Adjusted net loss decreased by approximately $1.4 million, or 11%, during the nine months ended September 30, 2016 when compared to the same period in 2015. The decrease in adjusted net loss for the nine month period is a result of the increase in revenue and a decrease in personnel and related costs, largely offset by increases in litigation fees and expenses related primarily to our ITC action. On a per share basis, our adjusted net loss per common share decreased by $0.34 per share, or 26%. This decrease is a result of the decrease in our adjusted net loss and a 22% increase in our weighted average common shares outstanding.
Reconciliation of Non-GAAP Financial Measures
The following table presents a
reconciliation of our net loss to the non-GAAP measure of adjusted net loss for the three and nine months ended September
30, 2016 and 2015, respectively
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
(in thousands)
|
|
September 30,
|
|
September 30,
|
|
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
Net loss
|
|
$
|
(2,334)
|
|
$
|
(3,136)
|
|
$
|
(15,838)
|
|
$
|
(13,754)
|
|
Excluded items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
1,423
|
|
|
196
|
|
|
1,488
|
|
|
1,083
|
|
Change in fair value of contingent payment obligation
|
|
|
726
|
|
|
-
|
|
|
3,033
|
|
|
-
|
|
Adjusted net loss
|
|
$
|
(185)
|
|
$
|
(2,940)
|
|
$
|
(11,317)
|
|
$
|
(12,671)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table presents a
reconciliation of our net loss
per common share
to the non-GAAP measure of adjusted net loss
per common share
for the three and nine months ended September
30, 2016 and 2015, respectively
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
September 30,
|
|
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
Basic and diluted net loss per common share
|
|
$
|
(0.18)
|
|
$
|
(0.32)
|
|
$
|
(1.33)
|
|
$
|
(1.40)
|
|
Excluded items
|
|
|
0.17
|
|
|
0.02
|
|
|
0.38
|
|
|
0.11
|
|
Adjusted net loss per common share
|
|
$
|
(0.01)
|
|
$
|
(0.30)
|
|
$
|
(0.95)
|
|
$
|
(1.29)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Off-Balance Sheet Transactions, Arrangements and Other Relationships
As of September
30, 2016, we had outstanding warrants to purchase
420,000
shares of our common stock. The estimated grant date fair value of these warrants of $
826,006
is included in shareholders’ equity in our
consolidated
balance sheets.
The outstanding warrants have an average exercise price of $2.21 per share and a weighted average remaining life of approximately 4 years.
Contractual Obligations
There have been no material changes in our contractual obligations as set forth in our Annual Report, except as follows:
In February 2016, we converted $825,000 in current liabilities
payable
to a related party to an unsecured promissory note. Interest on the note is payable monthly on the outstanding principal balance at a rate of 8% per annum and the note matures on December 31, 2017.
Also
,
in February 2016, as amended in May 2016, we entered into a litigation funding agreement with BKI whereby we received proceeds of $13 million in
exchange for BKI’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. The amount and timing of our repayment obligation is dependent upon the amount and timing of proceeds received by us for patent-related activities.
We repaid approximately $3.3 million of this obligation during the three months ended September 30, 2016. The estimated fair market value of the remaining obligation as of September 30, 2016 is approximately $12.4 million
.
Critical Accounting Policies
There have been no
changes in accounting policies from those stated in
our
Annual Report
, except as follows:
Restricted Cash and Cash Equivalents
Restricted cash and cash equivalents represent cash on hand and money market investments that are restricted for specific use in payment of legal fees and expenses related to
certain of
our patent infringement actions. The restricted money market investments have
weighted average
maturities of three months or less when purchased and are recorded at fair value.
Secured Contingent Payment Obligation
We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ASC”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows. Actual results could differ from the estimates made.
Revenue Recognition
We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes, sales of integrated circuit products, and engineering services. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when there is persuasive evidence of an arrangement, the amounts are fixed and determinable and the collectability is reasonably assured.
Revenue from the sale of products is recognized at the time of shipment to the customer or when the other criteria for revenue recognition are met, if later. Revenue from providing services is recognized when earned. Unearned revenue consists of product inventory held by a distributor and retainer payments received on services contracts.
The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statement of comprehensive loss when earned. We recognize revenues upon execution of a patent license and settlement agreement by both parties provided that the amounts are fixed and determinable, there are no significant undelivered obligations and collectability is reasonably assured. We do not recognize any revenue prior to the execution of an agreement as there is no reliable basis on which we can estimate the amounts related to the elements of the arrangement, or assess collectability. In addition, we do not recognize as revenue any consideration in the agreement that is contingent upon the occurrence of future events until such time that those future events occur.
Accounting for Share-Based Compensation
In
April
2016,
we adopted
the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2016-09,
“Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09
simplifies several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of
cash flows and forfeiture rate calculations.
We have elected to account for forfeitures of share-based equity awards as they occur
.
The adoption of ASU 2016-09 had no impact on our consolidated financial statements except for the reclassification of the value of shares withheld for payment of taxes in our accompanying consolidated statements of cash flows.
